U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16N2OS
Molecular Weight 296.387
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENTAZEPAM

SMILES

O=C1CN=C(C2=C(N1)SC3=C2CCCC3)C4=CC=CC=C4

InChI

InChIKey=AIZFEOPQVZBNGH-UHFFFAOYSA-N
InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20)

HIDE SMILES / InChI

Molecular Formula C17H16N2OS
Molecular Weight 296.387
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/bentazepam.html | https://www.ncbi.nlm.nih.gov/pubmed/1983365 | https://www.ncbi.nlm.nih.gov/pubmed/7008536 | http://www.sciencedirect.com/science/article/pii/S0011393X0580178X | https://www.ncbi.nlm.nih.gov/pubmed/9451703

Bentazepam (also known as Thiadipone, Tiadipona) is a benzodiazepine analog, used as a short-action anxiolytic. Bentazepam a thienodiazepine with the same main mechanism of action as the classic 1,4-benzodiazepines, is a short-action anxiolytic, with an elimination-half-life of 3 to 5 hours in healthy volunteers. Bentazepam possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. A severe benzodiazepine overdose with bentazepam may result in coma and respiratory failure. Adverse effects include dry mouth, somnolence, asthenia, dyspepsia, constipation, nausea and drug-induced lymphocytic colitis has been associated with bentazepam. Severe liver damage and hepatitis has also been associated with bentazepam. Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

bentazepam, administered orally at a dose of 25 mg with dosage intervals of 8, 12 and 24 h over 5 days of treatment.
Route of Administration: Oral
To examine the mitotic profiles of the Wg3h and CHE-3N cultures in the presence or absence of the Bentazepam the cells were seeded on sterile glass slides in petri dishes. Cells undergoing logarithmic phase growth, were treated with the Bentazepam for 18 (Don:Wg3h cells) and 22 h (CHE-3N cells) (a time corresponding to 1 cell cycle, allowing for mitotic delay) and harvested in 3:1 methanol/ acetic acid fixative, supplemented with Ca 2+ and Mg 2+ ions. Following a perchloric acid treatment to remove RNA, the cells were stained simultaneously with Brilliant blue R (to stain the spindle fibres blue) and Safranin O (to stain the chromosomes red).
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:24:28 GMT 2023
Edited
by admin
on Sat Dec 16 17:24:28 GMT 2023
Record UNII
66JKK43S1Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENTAZEPAM
INN   MART.   USAN   WHO-DD  
INN   USAN  
Official Name English
Bentazepam [WHO-DD]
Common Name English
BENTAZEPAM [USAN]
Common Name English
bentazepam [INN]
Common Name English
1,3,6,7,8,9-Hexahydro-5-phenyl-2H-[1]benzothieno[2,3-E]-1,4-diazepin-2-one
Systematic Name English
CI-718
Code English
2H-(1)BENZOTHIENO(2,3-E)-1,4-DIAZEPIN-2-ONE, 1,3,6,7,8,9-HEXAHYDRO-5-PHENYL-
Systematic Name English
BENTAZEPAM [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC N05BA24
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
NCI_THESAURUS C1012
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
Code System Code Type Description
EVMPD
SUB05733MIG
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID40897431
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
FDA UNII
66JKK43S1Z
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL1521495
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
MESH
C006129
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
WIKIPEDIA
BENTAZEPAM
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
PUBCHEM
135412795
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
SMS_ID
100000092532
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
INN
3726
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
CAS
29462-18-8
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
DRUG CENTRAL
315
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
NCI_THESAURUS
C74189
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
DRUG BANK
DB14719
Created by admin on Sat Dec 16 17:24:28 GMT 2023 , Edited by admin on Sat Dec 16 17:24:28 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY